These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26856706)

  • 1. Effects of commonly used intravitreal anti-vascular endothelial growth factor drugs on mesenchymal stem cells derived from the limbus and ciliary body.
    Acar U; Erginturk Acar D; Alpaslan Pinarli F; Demir MN; Beyazyildiz E; Ozdemir O; Gulmez Sevim D; Tiryaki M; Sobaci G
    Clin Exp Ophthalmol; 2016 Sep; 44(7):587-596. PubMed ID: 26856706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of commonly used intravitreal steroids on proliferation index of ciliary body-derived mesenchymal stem cells: an in vitro study.
    Demir MN; Acar U; Sobaci G; Pınarlı FA; Erginturk Acar D; Beyazyıldız E; Yesilyurt A; Delibasi T
    Cutan Ocul Toxicol; 2016 Mar; 35(1):53-7. PubMed ID: 25714111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of VEGF-A-inhibitors aflibercept and ranibizumab on the ciliary body and iris of monkeys.
    Ludinsky M; Christner S; Su N; Taubitz T; Tschulakow A; Biesemeier A; Julien-Schraermeyer S; Schraermeyer U
    Graefes Arch Clin Exp Ophthalmol; 2016 Jun; 254(6):1117-25. PubMed ID: 27106625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
    Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O
    Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular Endothelial Growth Factor (VEGF) Concentration Is Underestimated by Enzyme-Linked Immunosorbent Assay in the Presence of Anti-VEGF Drugs.
    Takahashi H; Nomura Y; Nishida J; Fujino Y; Yanagi Y; Kawashima H
    Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):462-6. PubMed ID: 26868748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells.
    Chae JB; Rho CR; Shin JA; Lyu J; Kang S
    Korean J Ophthalmol; 2018 Aug; 32(4):328-338. PubMed ID: 30091312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
    Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
    Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physician-Industry Interactions and Anti-Vascular Endothelial Growth Factor Use Among US Ophthalmologists.
    Taylor SC; Huecker JB; Gordon MO; Vollman DE; Apte RS
    JAMA Ophthalmol; 2016 Aug; 134(8):897-903. PubMed ID: 27356110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys.
    Tschulakow A; Christner S; Julien S; Ludinsky M; van der Giet M; Schraermeyer U
    PLoS One; 2014; 9(11):e113701. PubMed ID: 25415380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.
    Sheu SJ; Chao YM; Liu NC; Chan JY
    Acta Ophthalmol; 2015 Dec; 93(8):e631-43. PubMed ID: 25975662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Effects of Bevacizumab, Ranibizumab, and Aflibercept on the Viability and Wound Healing of Corneal Epithelial Cells.
    Kang S; Choi H; Rho CR
    J Ocul Pharmacol Ther; 2016 Dec; 32(10):671-676. PubMed ID: 27827554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions.
    Saenz-de-Viteri M; Fernández-Robredo P; Hernández M; Bezunartea J; Reiter N; Recalde S; García-Layana A
    Biochem Pharmacol; 2016 Mar; 103():129-39. PubMed ID: 26793998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.
    Yoshihara N; Terasaki H; Shirasawa M; Kawano H; Sonoda S; Yamaguchi M; Hashiguchi T; Hisatomi T; Ishibashi T; Sakamoto T
    Retina; 2017 Jan; 37(1):179-190. PubMed ID: 28005721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.
    Giurdanella G; Anfuso CD; Olivieri M; Lupo G; Caporarello N; Eandi CM; Drago F; Bucolo C; Salomone S
    Biochem Pharmacol; 2015 Aug; 96(3):278-87. PubMed ID: 26056075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications.
    Blaha GR; Brooks NO; Mackel CE; Pani A; Stewart AP; Price LL; Barouch FC; Chang J; Marx JL
    Retina; 2015 Mar; 35(3):577-81. PubMed ID: 25158942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
    Zehetner C; Bechrakis NE; Stattin M; Kirchmair R; Ulmer H; Kralinger MT; Kieselbach GF
    Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
    Parisi L; Fuhrer R; Zinkernagel M; Enzmann V
    Ophthalmologica; 2019; 241(3):137-142. PubMed ID: 30001546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to anti-VEGF-A treatment of endothelial cells in vitro.
    Puddu A; Sanguineti R; Traverso CE; Viviani GL; Nicolò M
    Exp Eye Res; 2016 May; 146():128-136. PubMed ID: 26771090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
    Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
    Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.